

1 Systematic review reveals multiple sexually antagonistic  
2 polymorphisms affecting human disease and complex  
3 traits

4  
5 Jon Alexander Harper<sup>1\*</sup>, Tim Janicke<sup>2,3</sup> and Edward H. Morrow<sup>4</sup>

6 \* Corresponding author

7 <sup>1</sup>Evolution, Behaviour and Environment Group, School of Life Sciences, John Maynard Smith  
8 Building, University of Sussex, Brighton, BN1 9QG, UK.

9 <sup>2</sup>Centre d'Écologie Fonctionnelle et Évolutive, UMR 5175, CNRS, Université de Montpellier,  
10 École Pratique des Hautes Études, Montpellier, France.

11 <sup>3</sup>Applied Zoology, Technical University Dresden, Zellescher Weg 20b, 01062 Dresden,  
12 Germany.

13 <sup>4</sup>Department of Environmental and Life Sciences, Karlstad University, 651 88, Karlstad,  
14 Sweden.

15  
16 Jon Alexander Harper ORCID: [0000-0002-1765-9990](https://orcid.org/0000-0002-1765-9990)

17 Tim Janicke ORCID: [0000-0002-1453-6813](https://orcid.org/0000-0002-1453-6813)

18 Edward H Morrow ORCID: [0000-0002-1853-7469](https://orcid.org/0000-0002-1853-7469)

19

20

21 Short title: Systematic review of sexually antagonistic genes in human disease

22

## 23 Abstract

24 An evolutionary model for sex differences in disease risk posits that alleles conferring higher  
25 risk in one sex may be protective in the other. These sexually antagonistic (SA) alleles are  
26 predicted to be maintained at frequencies higher than expected under purifying selection  
27 against unconditionally deleterious alleles, but there are apparently no examples in humans.  
28 Discipline-specific terminology, rather than a genuine lack of such alleles, could explain this  
29 disparity. We undertook a two-stage review of evidence for SA polymorphisms in humans  
30 using search terms from (i) evolutionary biology and (ii) biomedicine. While the first stage  
31 returned no eligible studies, the second revealed 51 genes with sex-opposite effects, 22  
32 increased disease risk or severity in one sex but protected the other. Those with net positive  
33 effects occurred at higher frequencies. None were referred to as SA. Our review reveals  
34 significant communication barriers to fields as a result of discipline-specific terminology.

35 148 words

36

## 37 Introduction

38 In species with separate sexes an evolutionary conflict at the level of individual genetic loci  
39 can occur, where alleles that are favoured by selection in one sex are selected against in the  
40 other (i.e intralocus sexual conflict, Parker, 1979). This sexually antagonistic (SA) form of  
41 selection is thought to be driven by differences in how the two sexes maximize their fitness  
42 and concomitant unequal variances in reproductive success. Research into SA selection has  
43 expanded recently with the recognition that it feeds into several important evolutionary  
44 processes. It is primarily thought to drive the evolution of sexual dimorphism and trait  
45 diversification (Lande, 1980; Pennell et al., 2016; Rice, 1984), including sex-biased gene  
46 expression (Ellegren and Parsch, 2007). As a potential driver of balancing selection, it has also  
47 been implicated in the maintenance of genetic variation (Connallon and Clark, 2013; Grieshop  
48 and Arnqvist, 2018) that would otherwise be eroded by directional selection. Most recently,  
49 it has been suggested that genetic variation at SA loci could contribute to the occurrence of a  
50 number of common human diseases (Morrow, 2015; Morrow and Connallon, 2013), which  
51 also show considerable variation between the sexes in terms of their prevalence, severity and  
52 age of onset (Ober et al., 2008; Rigby and Kulathinal, 2015).

53 Despite the interest in sexual antagonism as an evolutionary force, determining the  
54 identity of SA loci remains a major challenge (Ruzicka et al., 2020). An early empirical  
55 milestone in the field of sexual conflict was achieved by quantitative genetic studies  
56 demonstrating that genomes in a laboratory adapted population of *Drosophila melanogaster*  
57 harbour significant amounts of SA standing genetic variation (Chippindale et al., 2001; Rice,  
58 1992). A number of other systems have shown similar results, albeit using different methods,  
59 including invertebrates and vertebrates from both lab and wild populations (Bonduriansky  
60 and Chenoweth, 2009; Foerster et al., 2007; Mills et al., 2011). With the advent of advanced  
61 genomic tools, two model systems report specific examples of SA genetic loci: in Atlantic  
62 salmon (*Salmo salar*) the VGLL3 locus (Barson et al., 2015), and in *D. melanogaster* the DDT-  
63 R locus (Rostant et al., 2015), the Ala-278-Thr polymorphism in the mitochondrial genome  
64 (Camus et al., 2015), and multiple candidate loci from a recent genome-wide association  
65 study (Ruzicka et al., 2019).

66 Although humans have also been shown to experience SA selection for some  
67 quantitative traits (Garver-Apgar et al., 2011; Stearns et al., 2012; Stulp et al., 2012), and there

68 are numerous reports of genetic loci with sex-specific effects (i.e. effects that differ in  
69 magnitude between the sexes) on multiple complex traits or disease phenotypes (Gilks et al.,  
70 2014; Winkler et al., 2015), there are apparently no clear examples of SA loci in humans, which  
71 is inconsistent with theoretical expectations (Connallon and Clark, 2014). One potential  
72 explanation is that sexual antagonism is a weak selective force in humans, with sexual  
73 dimorphism being rather limited (Dixson, 2009; Short, 1979). This may indicate that  
74 concordant selection pressures between the sexes have dominated our evolutionary history.  
75 But the recent quantitative genetic studies challenge this view (Stearns et al., 2012; Stulp et  
76 al., 2012), and indeed theory predicts there is an inevitability to SA loci occurring in organisms  
77 with separate sexes (Connallon and Clark, 2014; Parker et al., 1972). Thus, there is a clear  
78 disparity between, on the one hand, theoretical expectations and quantitative genetic  
79 evidence that SA selection does occur in humans, and on the other hand, a complete lack of  
80 specific examples of SA loci. All this in the context of decades of research into how individual  
81 genetic variants influence disease profiles.

82 An alternative explanation for the absence of documented SA loci in humans is that  
83 since biomedical science does not use the same terminology for SA effects that evolutionary  
84 biology uses, there may in fact be examples that have been misclassified and therefore remain  
85 hidden in the literature. For example, genetic loci with sex-specific effects are frequently  
86 referred to as *sex-dependent* effects in the biomedical literature. Other terms are also used  
87 for related concepts, including *sex-different* effects. Furthermore, *sex-opposite* effects (i.e. a  
88 positive effect in one sex and a negative in the other) could be SA effects if the phenotype in  
89 question is deleterious, as disease phenotypes often are, since they can influence an  
90 individual's survival or reproductive fitness. The biomedical literature also frequently uses the  
91 terms *sex* and *gender* interchangeably, with *males* and *females* more often than not referred  
92 to as *men and women*, or *boys and girls* (Khramtsova et al., 2019). There is therefore ample  
93 scope for discipline-specific terms to be used for describing the same concept, which may  
94 hinder communication between disciplines and obscure examples of SA loci. Moreover,  
95 although there has been some progress in introducing concepts from evolutionary biology  
96 into the field of medicine (Nesse and Williams, 1994), those inroads have been relatively  
97 recent. It is therefore likely that the concepts of (intra)locus sexual conflict and sexual  
98 antagonism are not generally well known within biomedical science, and variants that may  
99 have SA effects on disease risk may not be referred to as such. A secondary related hypothesis

100 is that SA effects, when discovered, are discounted as errors as they do not match  
101 expectations that sex-differences in phenotype or genetic architecture are not important  
102 (Clayton and Collins, 2014). As a result, that may also lead them to be misclassified or simply  
103 go unreported, leading to a general publication bias.

104 For these reasons, we propose that a systematic review of the biomedical literature  
105 to identify SA loci in humans requires a specific and targeted set of search terms that would  
106 not normally be used within the field of evolutionary biology. We test this assumption by  
107 dividing our systematic review into two stages. In the first stage, we search for papers  
108 identifying specific genetic loci using terms directly relating to the concept of sexual  
109 antagonism and others utilized in evolutionary biology. We supplement this search with a  
110 second stage, where we develop a set of terms that we hypothesize may capture the same  
111 concept as sexual antagonism within the biomedical literature, although not explicitly stated  
112 as such, as well as additional terminology relating to possible alternatives for describing the  
113 two sexes. From our searches we also extracted data on sex-specific effect sizes and allele  
114 frequencies. We were then able to explore how effect sizes varied for the same alleles  
115 between the sexes, and test the prediction that SA alleles experiencing net positive selection  
116 between the sexes may achieve higher equilibrium frequencies than alleles that experience  
117 more symmetric or net negative patterns of selection (Morrow and Connallon, 2013). Our  
118 systematic review aims to advance our understanding of SA genes in humans, which show  
119 considerable and largely unexplained diversity in sexual dimorphism for disease phenotypes  
120 (Ober et al., 2006; Rigby and Kulathinal, 2015), but we also highlight how and why  
121 interdisciplinary research (in this case between biology and medicine) can sometimes fail,  
122 impeding scientific advances over significant periods of time.

## 123 [Methods](#)


124 For this systematic review we followed PRISMA guidance where possible (Moher et al., 2009).  
125 PubMed (<https://pubmed.ncbi.nlm.nih.gov/>) was searched for articles on 2<sup>nd</sup> December 2020  
126 with no time limit. The searches were carried out in two Stages, with the organism filter set  
127 to human in both stages. In Stage 1, eligible studies were required to report specific genetic  
128 variants or haplotypes that were referred to as sexually antagonistic or were an example of  
129 intralocus sexual conflict. To achieve this, we conducted a Boolean search for articles that  
130 used the terms “sexual antagonism” OR “sexually antagonistic” OR “intralocus sexual conflict”

131 AND “locus” OR “loci”, “gene” OR “snp” OR “polymorphism” OR “variant” OR “allele” in their  
132 abstract or title. The Stage 1 search returned 34 articles in total (full search term in the  
133 supplementary material; search output is accessible at  
134 <https://pubmed.ncbi.nlm.nih.gov/collections/60255050/?sort=pubdate>).

135 In Stage 2, studies were required to report specific genetic variants or haplotypes in  
136 humans with opposite effects in the two sexes on either complex traits, the outcome of a  
137 medical intervention, or disease risk/severity. We define complex traits as likely with a  
138 polygenic genetic architecture but are not directly related to a disease phenotype. In this  
139 second stage search terms were specifically designed to include papers from the biomedical  
140 literature that may have been missed in the first stage because they do not report their  
141 findings with terms normally found within the evolutionary biology literature. Again, we  
142 conducted a Boolean search for articles that used terms in their title or abstract to describe  
143 an opposite or different effect in the two sexes (“sex dependent”, “sex different”, “gender-  
144 dependent”, “sex AND opposite”, or “gender AND opposite”), or that capture this concept  
145 with alternative words for sex (“male AND female AND opposite” OR “men AND women AND  
146 opposite” OR “boys AND girls AND opposite”) AND (“locus” OR “loci” OR “gene” OR “snp” OR  
147 “polymorphism” OR “variant” OR “allele”). Full details of the search terms used and the  
148 numbers of articles returned are provided in the supplementary material. The Stage 2 search  
149 returned 881 papers (Figure 1) (full search term in the supplementary material; search output  
150 is accessible at <https://pubmed.ncbi.nlm.nih.gov/collections/60254985/?sort=pubdate>).

151 The abstracts of the papers from Stage 1 were then examined by EM and from Stage  
152 2 by JH, and any papers that had the possibility of reporting an opposite effect of a specific  
153 genetic locus on a complex trait, medical intervention or on disease risk/severity were  
154 considered for further screening. From Stage 1, no articles passed the screening. From Stage  
155 2, this screening produced a shortlist of 70 candidate papers  
156 (<https://pubmed.ncbi.nlm.nih.gov/collections/57906298/?sort=pubdate>) Both JH and EM  
157 then reviewed all the full texts of these candidate papers in detail. Papers were included in  
158 the final list if they described a sex-opposite or SA effect linked to a specific genetic locus or  
159 loci, and reported the effect to be statistically significant (at a P-value cut-off of <0.05). One  
160 additional paper was considered from an outside source.

161



162  
163  
164

**Figure 1.** PRISMA flow diagram for systematic review of sexually antagonistic loci in humans.

165 We converted all reported sex-specific effects into a standard effect size (Cohen's  $d$ )  
166 quantifying the magnitude of how a given variant affects the studied trait expressed in the  
167 given sex. Specifically, Cohen's  $d$  was computed based on the reported descriptive statistics  
168 ( $N$ , mean, standard error) or by conversion from other effect sizes (Odds ratio) and test  
169 statistics ( $F$ -values,  $t$ -values) using formulas reported elsewhere (Borenstein, 2009; Gurevitch  
170 et al., 2013, pp. 195–206; Lajeunesse, 2013). We sought information directly from the authors  
171 where these metrics were not possible to extract from the papers themselves (12 authors  
172 contacted, 5 responded, 3 responded with data, all later excluded as they did not fulfil the  
173 criteria for eligibility). We also recorded the gene name, locus (with accession/rs number  
174 where possible), trait affected and the frequency of the focal allele having the effect,  
175 hereafter referred to as *effect allele frequency*. Identification for the variants were taken from  
176 the studies where possible, but others necessitated searching the National Centre for  
177 Biotechnology Information (NCBI) to find the Reference SNP cluster ID for the variants  
178 described. Where effect allele frequencies were not reported, we used genotype frequencies  
179 to calculate effect allele frequency. Not all studies reported allele or genotype frequencies  
180 and so we attempted to supplement these data with allele frequencies from the 1000  
181 genomes database (Auton et al., 2015), since these show a strong correlation with effect allele  
182 frequencies reported in the studies reviewed (Pearson correlation:  $N = 25$   $r = 0.94$ ,  $P > 0.001$ ;  
183 Figure S1). However, using this approach we were only able to supplement our allele  
184 frequency data for one additional locus (rs7341475 in the *RELN* gene; Table 1).

185 If  $b_f$  and  $b_m$  represent the estimated effect of the focal allele in females and males  
186 respectively, then positive values of  $b_f$  or  $b_m$  imply that the allele is positively associated with  
187 disease expression, whereas negative values imply that the allele is negatively associated with  
188 disease expression. SA alleles are therefore defined as those with opposite effects between  
189 the sexes (i.e.  $b_f < 0 < b_m$  or  $b_m < 0 < b_f$ ). An evolutionary model of evolution at SA loci predicts  
190 that as the magnitude of the positive effect that an SA allele has outweighs the negative  
191 effect, the higher the frequency that allele can achieve (Morrow and Connallon, 2013). We  
192 therefore expect a negative relationship between the ratio of positive to negative effect sizes  
193 (hereafter referred to as the *effect size ratio*) and observed allele frequency. To investigate  
194 this, we calculated the effect size ratio by dividing the positive standardized effect size by the  
195 negative standardized effect size; when  $b_f < 0 < b_m$  effect size ratio was calculated as  $b_m / b_f$ ,  
196 and when  $b_m < 0 < b_f$  effect size ratio was calculated as  $b_f / b_m$ .



197 **Table 1. Genetic loci in humans showing sexually antagonistic effects on trait expression.** EAF, effect allele frequency (\* indicates allele  
 198 frequency derived from 100 genomes database); M, male; F, female. Background colours denote instances where genes and/or variants  
 199 appear more than once in the list.  
 200

Trait	Gene	Locus	EAF	M Effect	M Effect SE	F Effect	F Effect SE	Reference
<b>Complex traits</b>								
Concentration performance score	FADS1/2	rs1535	0.672	0.2275	0.1065	-0.2394	0.1116	(Lauritzen et al., 2017)
Reading speed, number of sentences	FADS1/2	rs174448	0.642	0.5511	0.1069	-0.6074	0.1129	(Lauritzen et al., 2017)
Reading speed, number of sentences	ELOVL5	rs2397142	0.695	-0.1963	0.1042	0.2364	0.1095	(Lauritzen et al., 2017)
Reading speed, correct sentences	FADS1/2	rs174448	0.642	0.6599	0.1077	-0.3451	0.1112	(Lauritzen et al., 2017)
Speed-dating success	OPRM1	rs1799971	0.922	0.4697	0.2275	-0.53	0.2856	(Wu et al., 2016)
Speed-dating success	HTR2A	rs6311	0.418	-0.4826	0.1982	0.4702	0.1964	(Wu et al., 2016)
Waist-hip-ratio (BMI adjusted)	SIM1	rs17185536	0.76	-0.0166	0.008	0.0264	0.0067	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	NMU	rs3805389	0.28	-0.0139	0.0067	0.0261	0.006	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	GNPNAT1	rs4898764	0.53	0.0208	0.0066	-0.0165	0.0059	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	SGCZ	rs17470444	0.71	0.0345	0.0081	-0.0149	0.0068	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	IQGAP2	rs2069664	0.53	0.0244	0.0078	-0.0183	0.0067	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	SLC2A3	rs741361	0.6	0.0272	0.0079	-0.0196	0.0067	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	IRS1	rs2673140	0.38	0.022	0.0066	-0.0209	0.0059	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	TTN	rs2042995	0.23	0.0198	0.0066	-0.022	0.0078	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	RXRA	rs10881574	0.07	0.0268	0.008	-0.0191	0.0067	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	PTPRD	rs7042428	0.98	0.0244	0.0071	-0.0166	0.0063	(Winkler et al., 2015)
Waist-hip-ratio (BMI adjusted)	CECR2	rs17809093	0.04	0.0294	0.0091	-0.024	0.0077	(Winkler et al., 2015)
Reaction time (RT) in the Stroop task, congruent condition	CHRNA5	rs3841324	0.406	-1.5421	0.3857	0.9945	0.2517	(Schneider et al., 2015)
Reaction time (RT) in the Stroop task, incongruent condition	CHRNA5	rs3841324	0.406	-1.6215	0.389	1.0215	0.2521	(Schneider et al., 2015)
Reaction time (RT) in the Negative priming task	CHRNA5	rs3841324	0.406	-1.675	0.3912	0.6299	0.247	(Schneider et al., 2015)

Borderline personality traits after maltreatment	OXTR	rs53576	0.738	-0.3429	0.0881	0.2066	0.0857	(Cicchetti et al., 2014)
Borderline personality traits after maltreatment	FKBP5	CATT haplotype	-	0.2041	0.0877	-0.195	0.0857	(Cicchetti et al., 2014)
fluid intelligence	C16orf62 (OXTR)	rs226849	0.46	-0.3949	0.1869	0.494	0.1814	(Kiy et al., 2013)
face perception	C16orf62 (OXTR)	rs226849	0.46	-0.5819	0.1909	0.3498	0.1788	(Kiy et al., 2013)
face memory	C16orf62 (OXTR)	rs226849	0.46	-0.3679	0.1864	0.3562	0.1789	(Kiy et al., 2013)
Hippocampal volume	SLC6A4	rs25531	0.39	-		-		(Price et al., 2013)
Sociopathy (in alcoholics)	SLC6A4	rs25531	0.51	-		-		(Herman et al., 2011)
systolic blood pressure S_NIGHT	PON1	rs3917542	-	-0.1047	0.0637	0.1129	0.0645	(Padmanabhan et al., 2010)
systolic blood pressure S_NIGHT	PON3	rs17884563	-	-0.1482	0.0637	0.1061	0.0645	(Padmanabhan et al., 2010)
systolic blood pressure S_CLIN	EDNRB	rs1335803	-	-0.1308	0.0637	0.1129	0.0645	(Padmanabhan et al., 2010)
diastolic blood pressure D_NIGHT	DRD1	rs265974	-	-0.1482	0.0637	0.1502	0.0646	(Padmanabhan et al., 2010)
diastolic blood pressure D_HOME	SLC4A2	rs2303933	-	-0.1482	0.0637	0.1325	0.0646	(Padmanabhan et al., 2010)
diastolic blood pressure D_CLIN	LPL	rs17410577	-	-0.1047	0.0637	0.1775	0.0647	(Padmanabhan et al., 2010)
Psychological Stress	BDNF	rs6265	0.149	-		-		(Shalev et al., 2009)
BMI standard deviation score (children)	FAS	rs2228305	0.0312	-0.552	0.2259	0.4427	0.2075	(Korner et al., 2007)
Pain sensitivity	OPRM1	rs1799971	0.8817	-		-		(Fillingim et al., 2005)
Central DBP	REN	rs6693954	0.22	-0.4444	0.2132	1.1052	0.3923	(Ljungberg et al., 2014)
<b><u>Disease risk/severity</u></b>								
Graves ophthalmopathy in GD	PRR3	rs2074503	0.3586	0.4397	0.1682	-0.2185	0.0851	(Liu et al., 2014)
Colorectal cancer	LTA	rs1041981	0.32	-0.0722	0.0368	0.1027	0.0453	(Sainz et al., 2012)
Arterial blood pressure	PPAR	rs1801282	0.1213	-		-		(Franck et al., 2012)
Schizophrenia risk	RELN	rs7341475	0.851*	1.2396	0.2819	-0.762	0.3662	(Ovadia and Shifman, 2011)
Colon cancer survival	ESR2	(CA)n repeats	-	0.2272	0.0962	-0.2046	0.1205	(Press et al., 2011)
Schizophrenia risk	DAO	rs2070586	0.2729	0.1982	0.0888	-0.2537	0.0908	(Kim et al., 2010)

T2DM, fasting glucose	SCARB1	rs9919713	0.04	0.1865	0.0853	-0.2515	0.0697	(McCarthy et al., 2009)
Depression	SLC6A4	rs25531	0.4586	0.5404	0.2277	-0.3996	0.1859	(Sjoberg et al., 2006)
Infertility in cystic fibrosis	CFTR	rs213950	0.417931	-		-		(Morea et al., 2005)
Bone mineral density	APOE	rs429358	0.0798	-		-		(Wong et al., 2005)
Narcolepsy severity	COMT	Long allele	0.4588	1.3596	0.3878	-2.2152	0.4871	(Dauvilliers et al., 2001)
Nonsyndromic cleft lip	IMPK	rs11142081	0.863	1.2156	0.0937	-1.1161	0.0783	(Carlson et al., 2018)
Nonsyndromic cleft lip	IMPK	rs72804706	0.898	-0.816	0.0906	2.0665	0.0908	(Carlson et al., 2018)
Nonsyndromic cleft lip	IMPK	rs77590619	0.744	-0.8577	0.0904	1.2291	0.0804	(Carlson et al., 2018)
Allergy	ACP1	A* allele (CG haplotype)	-	-		-		(Gloria-Bottini et al., 2007)
Hepatitis C susceptibility	IL-12B	rs3212227	0.3463	-		-		(Youssef et al., 2013)
RSV severity	IL-9	rs2069885	0.15	0.1888	0.0933	-0.2794	0.0957	(Schuurhof et al., 2010)
CV risk marker (plasma fatty acid composition)	FABP2	rs1799883	0.287	-		-		(Gastaldi et al., 2007)
Bone mineral density	NR3C1	GCAG haplotype	-	0.6854	0.3676	-0.9029	0.4311	(Peng et al., 2008)
Anxiety	NGF	rs6330	0.451	0.4562	0.18	-0.4674	0.1817	(Lang et al., 2008)
Melanoma risk	RNASEL, miR-146a	AG/AA and C haplotype	-	0.4525	0.1564	-0.3553	0.174	(Sangalli et al., 2017)

202 Thus, SA alleles with a greater beneficial effect will have a smaller, more negative  
203 effect size ratio ( $<-1$ ), while SA alleles that have a greater deleterious effect will have a larger  
204 effect size ratio ( $>-1$ ), up to a maximum value of 0 (positive values occur when the effect is  
205 positive or negative in both sexes, but the allele would then no longer be defined as a SA  
206 allele).

207 We modelled how effect allele frequency changes with effect size ratio using a  
208 generalized linear model (GLM), weighted by the inverse of the variance of the effect sizes  
209 such that data points with smaller variance have a higher weight, since smaller sample sizes  
210 were associated with larger and more variable effect sizes (Figure S2). We initially also  
211 included trait class and its interaction with effect size ratio as a fixed factor with two levels  
212 (complex trait and disease trait/severity), since alleles that influence complex traits in  
213 opposite directions are not necessarily under SA selection and so may not behave in the way  
214 predicted, whereas alleles influencing disease traits, unless very late acting, are more likely  
215 to show a closer relationship with marginal effects on fitness. As a response variable, effect  
216 allele frequency is limited between 0 and 1, so we looked at allele counts to allow allele  
217 frequency to vary freely. GLMs with binomial error distribution showed substantial  
218 overdispersion, so we used a quasibinomial function to address this issue (Payne et al., 2018).  
219 We used a Chi-squared test to infer significance of the two predictor variables and their  
220 interaction. The full model indicated that the interaction term and trait class have no  
221 significant effect, so that we report the fit of the reduced model which only includes effect  
222 size ratio. We also subsequently modelled the data for the two trait classes (complex traits  
223 and disease risk/severity) separately, again using a quasibinomial distribution function, to see  
224 if the result was replicated in these smaller subsets of the data. The raw data and R script is  
225 available for replicating the analyses and figures we present (Supplementary Material).


## 226 Results

227 The Stage 1 search found no articles that described genetic loci in humans with effects that  
228 were sexually antagonistic. In contrast, the Stage 2 search identified 32 articles that described  
229 variants with statistically significant sex-opposite or SA effects (Figure 1;  
230 <https://pubmed.ncbi.nlm.nih.gov/collections/60278165/?sort=pubdate>). From the studies  
231 examined, 51 SA variants were identified (Table 1), affecting 21 different complex traits (30  
232 loci) and 19 disease risk/severity traits (21 loci), with a large range of effect sizes. There were

233 no variants affecting medical intervention traits that passed the screening process. The  
234 majority of alleles had effect sizes of similar absolute values in the two sexes, with larger  
235 effects tending to show greater differences on absolute effect size (Figure S3).

236 We found 22 studies provided sufficient data to allow the relationship between effect  
237 size ratio and effect allele frequency to be explored by statistical modelling. Trait class and its  
238 interaction with effect size ratio were initially included in the model but neither were found  
239 to have a significant effect (GLM: trait class  $dfs = 1,35$ , deviance =  $15.5 \times 10^3$ ,  $P = 0.965$ ;  
240 interaction  $dfs = 1,34$ , deviance = 1476,  $P = 0.989$ ) and were therefore excluded from the  
241 subsequent model in which effect size ratio was found to relate negatively to effect allele  
242 frequency, as predicted (GLM: estimate  $\pm SE = -1.10 \pm 0.50$ ,  $dfs = 1,36$ , deviance =  $38.7 \times 10^6$ ,  
243  $P = 0.024$ ; Figure 2). For three loci there were data on effect sizes for more than one trait  
244 (Table 1), which introduced a degree of non-independence between these values in the  
245 dataset. However, resampling the data with effect sizes for only one trait for these three loci  
246 in turn and modelling these datasets in the same way (18 individual GLMs,  $dfs = 1,31$ ) did not  
247 change the results qualitatively (minimum, maximum: model estimate = -1.0963, -1.0964;  
248 deviance =  $38.72 \times 10^6$ ,  $38.73 \times 10^6$ ;  $P = 0.03618$ , 0.03620).

249 Although the interaction term between trait type and effect size ratio was not  
250 significant we wanted to investigate whether the negative relationship between effect size  
251 ratio and effect allele frequency across all loci was repeated when the data was divided  
252 according to trait class, since while opposite effects on disease risk/severity may show a direct  
253 relationship with SA fitness effects, complex traits may or may not be experiencing SA  
254 selection, even if effects are in opposite directions in the two sexes. However, although the  
255 trends were both again negative as predicted, the generalized linear models of these smaller  
256 datasets were only marginally significant (complex traits model estimate  $\pm SE = -1.10 \pm 0.61$ ,  
257  $dfs = 1,24$ , deviance =  $38.7 \times 10^6$ ,  $P = 0.065$ ; disease risk/severity model estimate  $\pm SE = -1.34$   
258  $\pm 0.77$ ,  $dfs = 1,10$ , deviance =  $5.14 \times 10^4$ ,  $P = 0.053$ ; Figure S4). As for the full dataset, there  
259 was some lack of independence for the complex traits subset which contained loci with effect  
260 sizes for more than one trait. Again, resampling and modelling these datasets in the same  
261 way (18 individual glms,  $dfs = 1, 22$ ) did not change the results quantitatively (minimum,  
262 maximum: model estimate = -1.0960, -1.0961; deviance =  $38.669 \times 10^6$ ,  $38.675 \times 10^6$ ;  $P =$   
263 0.07774, 0.07776).



264

265 **Figure 2. The relationship between effect allele frequency and effect size ratio.** Point size  
266 varies according to the variance of effect size ratio - larger points have smaller variance and  
267 therefore a larger weighting in the model. The vertical dotted line represents the switch point  
268 between a net-negative effect of a particular locus (effect size ratio  $>-1$ ) and a net positive  
269 effect (effect size ratio  $<-1$ ). The blue line represents the predicted values derived from the  
270 generalized linear model fitted to the data (see Results).

## 271 Discussion

272 The Stage 1 literature search of our systematic review focussed on finding reports of specific  
273 genetic loci in humans with evidence for SA effects using terminology normally associated  
274 with the evolutionary concepts of sexual conflict or sexual antagonism. The Stage 2 search  
275 sought equivalent evidence, but used search terms that we anticipated would be used by  
276 scientists outside the field of evolutionary biology, who may not use the same terminology.  
277 Although the Stage 1 search did not find any examples of SA loci occurring in humans, the  
278 Stage 2 search identified 51 genetic loci across 39 studies that had ostensibly SA effects, but  
279 were not described as such. Clearly then the Stage 1 review failed to identify multiple relevant  
280 reports going back some 20 years because the terminology used in those reports did not  
281 match the conceptual framework of the search. The Stage 2 search may also be a lower limit  
282 given searches of other larger databases may also harbour further examples (see below).  
283 Although not yet validated, these reports nonetheless represent a substantial body of  
284 evidence that humans, like other organisms with separate sexes (Bonduriansky and  
285 Chenoweth, 2009), inevitably experience SA selection for a wide range of complex traits  
286 (Connallon and Clark, 2014; Garver-Apgar et al., 2011; Stearns et al., 2012; Stulp et al., 2012),  
287 as well as for a range of diseases.

288 A key prediction from a population genetic model of SA genetic variation is that SA  
289 alleles are expected to achieve higher equilibrium frequencies, without necessarily going to  
290 fixation, as the relative magnitude of the positive effect in one sex outweighs the negative  
291 effect in the opposite sex i.e. an increasingly negative effect size ratio (Morrow and Connallon,  
292 2013). We found clear support for this prediction, with a negative relationship between effect  
293 size ratio and allele frequency when examining all complex traits and diseases together (Fig  
294 2), although this relationship was only marginally significant when complex or disease trait  
295 classes were modelled separately (Fig S3). These results lend support to the view that the loci  
296 identified are genuinely experiencing SA selection, and although it is difficult to discern how  
297 selection acts on trait size in males and females for complex traits we would not expect the  
298 frequencies of disease-causing alleles to be so high under a mutation-selection balance. We  
299 were not able to look at the evolutionary history or age of these alleles due to limited  
300 information ( $n = 8$ ) (Albers and McVean, 2018), it would nonetheless be valuable to examine  
301 the population dynamics of these alleles over a broad timescale.

302           The loci showed a very broad range of effect sizes, from small to very large, with a  
303 generally symmetrical inverse relationship between effect size in one sex and the other  
304 (Figure S2), which is generally expected, since our screening process necessarily excluded  
305 studies reporting effects in the same direction across the two sexes. Nonetheless, it is striking  
306 just how large some of the effects were, with very large negative effects in one sex  
307 simultaneously occurring with similarly large positive effects. Larger and more variable effect  
308 sizes are expected when sample sizes are small, a pattern we also found, which motivates  
309 further investigation of the traits and loci included in this review to elucidate more accurate  
310 estimates of real effect sizes.

311           The loci themselves fall within genes that influence a broad range of phenotypes,  
312 including morphological, physiological and behavioural complex traits, and a similarly diverse  
313 range of disease types, including various cancers, neurological disorders and immune system  
314 processes (see Table 1). For the most part, the diseases appear to be early-acting rather than  
315 late-onset, with the exception of perhaps bone mineral density. As such, it seems reasonable  
316 that an allele that increases disease risk or severity in these cases will indeed have a  
317 concomitant reduction in marginal fitness. Although a single large study identified several loci  
318 related to BMI adjusted waist-to-hip ratio, there is generally no overall bias towards one  
319 particular trait or disease class. The total number of loci is relatively small however, which  
320 may limit power to identify such biases if they exist. We also did not find any examples of SA  
321 loci on the X-chromosome, which may or may not be a hotspot of sexual antagonism (Fry,  
322 2010; Rice, 1984; Ruzicka and Connallon, 2020). This was expected given that it is commonly  
323 not included in genome-wide analyses (Wise et al., 2013), although most of the papers we  
324 reviewed were candidate gene studies. Nonetheless, we anticipate further examples may be  
325 identified should data from the X-chromosome be included systematically in association  
326 studies.

327           We also found evidence that some traits are influenced by more than one genetic  
328 variant in sex-opposite or SA ways ( $n=8$ ), or that some specific variants have pleiotropic  
329 effects on more than one trait or disease in a sex-opposite or SA way ( $n=6$ ; see Table 1). This  
330 complexity in the genetic architecture of traits or diseases may make conflict resolution  
331 particularly difficult, as a change in the allele at a single genetic locus experiencing SA  
332 selection may simultaneously influence multiple genes or phenotypes in both sexes in  
333 divergent ways (Fitzpatrick, 2004; Pennell and Morrow, 2013). Consequently, this may explain



334 the persistence of intralocus sexual conflict at these loci. It may be that some of the remaining  
335 loci also have as yet unidentified pleiotropic effects with other traits or there are as yet  
336 unidentified SA loci influencing those same traits or diseases. Of the 51 variants identified, 4  
337 were confirmed to be haplotypes. Such variants, consisting of two or more SNPs in linkage  
338 disequilibrium having a joint effect, could also present a problem for conflict resolution, since  
339 the ability of selection to act on any individual locus independent of the others in the linkage  
340 block is reduced for linked loci. This issue may also extend to other single variants reported  
341 here if they also occur in linkage blocks.

342 Although we have identified multiple genetic loci with either sex-opposite or SA  
343 effects these are likely outnumbered by those with either sex-specific (same direction but  
344 different magnitude) or sex-limited effects. For instance, Winkler et al. (2015) report 44 loci  
345 with sex-specific or sex-limited effects but only 11 with sex-opposite effects. Several other  
346 genome-wide association studies report sex-specific effects in several human diseases  
347 (Khramtsova et al., 2019), and a recent (non-systematic) review identified 37 SNPs with sex-  
348 dependent effects (Gilks et al., 2014). Detection of loci with SA versus sex-specific or sex-  
349 limited effects may differ systematically since we expect SA loci are more likely to persist at  
350 intermediate frequencies than loci with sex-specific effects (i.e. that differ between the sexes  
351 in magnitude but not sign). A larger systematic review that targeted variants with sex-specific  
352 or sex-dependent effects would therefore be a valuable contribution and enable us to more  
353 clearly understand how important SA alleles are relative to the broader context of genes with  
354 non-identical effects in the two sexes.

355 A key gap in our knowledge is whether the putative examples of sex-opposite or SA  
356 alleles presented here can be validated using independently derived datasets in the same or  
357 different sub-populations. For this, focussing on those variants associated with sex-  
358 differential disease risk would naturally be the most fruitful for advancing our knowledge of  
359 sexual antagonism in human disease. We therefore encourage specialists for the particular  
360 disease groups presented in Table 1 to include in the future the potential for SA genetic  
361 effects to occur when designing studies and analysing data. It is also important for all studies  
362 to report results in sufficient detail so that effect sizes can be calculated (if not given) as well  
363 as allele frequency data. Unfortunately, 17 studies failed to do this, so could not be included  
364 in our review and subsequent test of the evolutionary model. More generally, our study  
365 reinforces the view that sex is an important factor in shaping genetic associations with human

366 traits and disease, even in divergent and contradictory ways, and so should always be  
367 considered when investigators examine genetic associations with phenotypes (Lee, 2018;  
368 Ober et al., 2008).

369         There is a possibility that some bias exists in the PubMed database against papers  
370 from the field of evolutionary biology, and if we had used another database then both stages  
371 would have returned valid papers. We subsequently (14<sup>th</sup> Dec 2020) sought to investigate this  
372 possibility with additional searches of Scopus and Web of Science. Repeating the Stage 1  
373 search initially returned 85 papers in Web of Science (Basic search of Topic, refined by  
374 “Human” within results) and 71 papers in Scopus (include keywords “Human”, exclude “Non-  
375 Human”), but again no papers made it through the screening process. Repeating the Stage 2  
376 search returned a much larger number of studies in both Web of Science (4,573; Basic search  
377 of Topic, refined by “Human” within results) and Scopus (6,616; Advanced search of Title-  
378 Abstract, filter: include human and humans, exclude nonhumans, Articles only), with 8,604  
379 unique records. This large number of records is too many to currently screen and may harbour  
380 further examples of SA loci in humans, but it is noteworthy that the majority of the initial list  
381 of studies found during Stage 2 using PubMed were also found in the other two databases  
382 (712 out of 881) as well as 28 out of the screened list of 32 studies identified in the current  
383 systematic review.

384         The disparity between the two stages of the review process provides a remarkable  
385 example of how discipline-specific terminology and concepts can hinder scientific  
386 communication between fields for substantial periods of time. For many of the studies  
387 identified in this review, the focus of the research was not on quantifying or even identifying  
388 sex-specific genetic effects in traits or disease, although they were tested for. The responses  
389 to such findings varied. Some framed these results as a major finding, others merely made  
390 note of them, with one suggesting that since the genetic associations were in opposite  
391 directions in the two sexes then it should be regarded as a false positive (Wong et al., 2005).  
392 It is possible, or even likely then that there exists a publication bias in the biomedical sciences  
393 against studies with apparently incongruous sex-opposite or SA effects, perhaps in part  
394 because the evolutionary framework that may provide a context for understanding those  
395 results is not generally appreciated or known. Of course, for evolutionary biologists interested  
396 in the role of SA selection on human traits and disease, this is clearly a problem. For many  
397 years no specific examples of SA loci were known in humans, and yet the first putative

398 examples in fact appeared in the literature two decades ago. Our systematic review therefore  
399 provides a concrete illustration of how advances to both fields have likely been hampered by  
400 a limited understanding of the theoretical framework and terminology used by the  
401 neighbouring field.

402         How can communication between the fields of medicine and evolutionary biology be  
403 facilitated? We do not have a comprehensive answer but clearly training in, or an increased  
404 awareness of, evolutionary medicine for scientists in both camps would probably be  
405 beneficial. The topic of evolutionary biology now forms a key part of the education for some  
406 biomedical scientists and clinicians. Similarly, evolutionary medicine is now frequently  
407 included in fundamental textbooks on evolution, and is being taught to students of  
408 evolutionary biology as part of their degree courses. These changes have been relatively  
409 recent, are far from being universally employed, but they should be encouraged. Funders of  
410 primary research are also now actively encouraging or obliging researchers to include sex as  
411 a factor when designing their studies (Clayton and Collins, 2014), although this may simply  
412 result in studies that aim to control for rather than investigate these effects explicitly.  
413 Consequently even this remedy may still preclude a deeper understanding of the origins of  
414 some human diseases.

415

## 416 [Acknowledgements](#)

417 We thank Jessica Abbott, Tim Connallon and Filip Ruzicka for comments on a previous version  
418 of the MS. Funding was provided by the Swedish Research Council (Grant number: 2019-  
419 03567) and by the Royal Society to EHM as a University Research Fellowship and  
420 Enhancement Award. TJ was funded by the Centre national de la recherche scientifique  
421 (CNRS) and the German Research Foundation (DFG grant number: JA 2653/2-1).

422

## 423 [Competing Interest Statement](#)

424 The authors have declared no competing interest.

425

## 426 References

- 427 Albers, P.K., McVean, G., 2018. Dating genomic variants and shared ancestry in population-  
428 scale sequencing data (preprint). *Genomics*. <https://doi.org/10.1101/416610>
- 429 Auton, A., Abecasis, G.R., Altshuler, D.M., Durbin, R.M., Abecasis, G.R., Bentley, D.R.,  
430 Chakravarti, A., Clark, A.G., Donnelly, P., Eichler, E.E., Flicek, P., Gabriel, S.B., Gibbs,  
431 R.A., Green, E.D., Hurler, M.E., Knoppers, B.M., Korbel, J.O., Lander, E.S., Lee, C.,  
432 Lehrach, H., Mardis, E.R., Marth, G.T., McVean, G.A., Nickerson, D.A., Schmidt, J.P.,  
433 Sherry, S.T., Wang, J., Wilson, R.K., Gibbs, R.A., Boerwinkle, E., Doddapaneni, H., Han,  
434 Y., Korchina, V., Kovar, C., Lee, S., Muzny, D., Reid, J.G., Zhu, Y., Wang, J., Chang, Y.,  
435 Feng, Q., Fang, X., Guo, X., Jian, M., Jiang, H., Jin, X., Lan, T., Li, G., Li, J., Li, Y., Liu, S.,  
436 Liu, X., Lu, Y., Ma, X., Tang, M., Wang, B., Wang, G., Wu, H., Wu, R., Xu, X., Yin, Y.,  
437 Zhang, D., Zhang, W., Zhao, J., Zhao, M., Zheng, X., Lander, E.S., Altshuler, D.M.,  
438 Gabriel, S.B., Gupta, N., Gharani, N., Toji, L.H., Gerry, N.P., Resch, A.M., Flicek, P.,  
439 Barker, J., Clarke, L., Gil, L., Hunt, S.E., Kelman, G., Kulesha, E., Leinonen, R., McLaren,  
440 W.M., Radhakrishnan, R., Roa, A., Smirnov, D., Smith, R.E., Streeter, I., Thormann, A.,  
441 Toneva, I., Vaughan, B., Zheng-Bradley, X., Bentley, D.R., Grocock, R., Humphray, S.,  
442 James, T., Kingsbury, Z., Lehrach, H., Sudbrak, R., Albrecht, M.W., Amstislavskiy, V.S.,  
443 Borodina, T.A., Lienhard, M., Mertes, F., Sultan, M., Timmermann, B., Yaspo, M.-L.,  
444 Mardis, E.R., Wilson, R.K., Fulton, L., Fulton, R., Sherry, S.T., Ananiev, V., Belaia, Z.,  
445 Beloslyudtsev, D., Bouk, N., Chen, C., Church, D., Cohen, R., Cook, C., Garner, J.,  
446 Hefferon, T., Kimelman, M., Liu, C., Lopez, J., Meric, P., O'Sullivan, C., Ostapchuk, Y.,  
447 Phan, L., Ponomarov, S., Schneider, V., Shekhtman, E., Sirotkin, K., Slotta, D., Zhang,  
448 H., McVean, G.A., Durbin, R.M., Balasubramaniam, S., Burton, J., Danecek, P., Keane,  
449 T.M., Kolb-Kokocinski, A., McCarthy, S., Stalker, J., Quail, M., Schmidt, J.P., Davies,  
450 C.J., Gollub, J., Webster, T., Wong, B., Zhan, Y., Auton, A., Campbell, C.L., Kong, Y.,  
451 Marnett, A., Gibbs, R.A., Yu, F., Antunes, L., Bainbridge, M., Muzny, D., Sabo, A.,  
452 Huang, Z., Wang, J., Coin, L.J.M., Fang, L., Guo, X., Jin, X., Li, G., Li, Q., Li, Y., Li, Z., Lin,  
453 H., Liu, B., Luo, R., Shao, H., Xie, Y., Ye, C., Yu, C., Zhang, F., Zheng, H., Zhu, H., Alkan,  
454 C., Dal, E., Kahveci, F., Marth, G.T., Garrison, E.P., Kural, D., Lee, W.-P., Fung Leong,  
455 W., Stromberg, M., Ward, A.N., Wu, J., Zhang, M., Daly, M.J., DePristo, M.A.,  
456 Handsaker, R.E., Altshuler, D.M., Banks, E., Bhatia, G., del Angel, G., Gabriel, S.B.,  
457 Genovese, G., Gupta, N., Li, H., Kashin, S., Lander, E.S., McCarroll, S.A., Nemesh, J.C.,  
458 Poplin, R.E., Yoon, S.C., Lihm, J., Makarov, V., Clark, A.G., Gottipati, S., Keinan, A.,  
459 Rodriguez-Flores, J.L., Korbel, J.O., Rausch, T., Fritz, M.H., Stütz, A.M., Flicek, P., Beal,  
460 K., Clarke, L., Datta, A., Herrero, J., McLaren, W.M., Ritchie, G.R.S., Smith, R.E.,  
461 Zerbino, D., Zheng-Bradley, X., Sabeti, P.C., Shlyakhter, I., Schaffner, S.F., Vitti, J.,  
462 Cooper, D.N., Ball, E.V., Stenson, P.D., Bentley, D.R., Barnes, B., Bauer, M., Keira  
463 Cheetham, R., Cox, A., Eberle, M., Humphray, S., Kahn, S., Murray, L., Peden, J.,  
464 Shaw, R., Kenny, E.E., Batzer, M.A., Konkel, M.K., Walker, J.A., MacArthur, D.G., Lek,  
465 M., Sudbrak, R., Amstislavskiy, V.S., Herwig, R., Mardis, E.R., Ding, L., Koboldt, D.C.,  
466 Larson, D., Ye, K., Gravel, S., The 1000 Genomes Project Consortium, Corresponding  
467 authors, Steering committee, Production group, Baylor College of Medicine, BGI-  
468 Shenzhen, Broad Institute of MIT and Harvard, Coriell Institute for Medical Research,  
469 European Molecular Biology Laboratory, E.B.I., Illumina, Max Planck Institute for  
470 Molecular Genetics, McDonnell Genome Institute at Washington University, US  
471 National Institutes of Health, University of Oxford, Wellcome Trust Sanger Institute,

- 472 Analysis group, Affymetrix, Albert Einstein College of Medicine, Bilkent University,  
473 Boston College, Cold Spring Harbor Laboratory, Cornell University, European  
474 Molecular Biology Laboratory, Harvard University, Human Gene Mutation Database,  
475 Icahn School of Medicine at Mount Sinai, Louisiana State University, Massachusetts  
476 General Hospital, McGill University, National Eye Institute, N., 2015. A global  
477 reference for human genetic variation. *Nature* 526, 68–74.  
478 <https://doi.org/10.1038/nature15393>
- 479 Barson, N.J., Aykanat, T., Hindar, K., Baranski, M., Bolstad, G.H., Fiske, P., Jacq, C., Jensen,  
480 A.J., Johnston, S.E., Karlsson, S., Kent, M., Moen, T., Niemelä, E., Nome, T., Næsje,  
481 T.F., Orell, P., Romakkaniemi, A., Sægrov, H., Urdal, K., Erkinaro, J., Lien, S., Primmer,  
482 C.R., 2015. Sex-dependent dominance at a single locus maintains variation in age at  
483 maturity in salmon. *Nature* 528, 405–408. <https://doi.org/10.1038/nature16062>
- 484 Bonduriansky, R., Chenoweth, S.F., 2009. Intralocus sexual conflict. *Trends Ecol Evol* 24,  
485 280–288.
- 486 Borenstein, M., 2009. Converting Among Effect Sizes, in: *Introduction to Meta-Analysis*. John  
487 Wiley & Sons, Ltd, pp. 45–49. <https://doi.org/10.1002/9780470743386.ch7>
- 488 Camus, M.F., Wolf, J.B.W., Morrow, E.H., Dowling, D.K., 2015. Single Nucleotides in the  
489 mtDNA Sequence Modify Mitochondrial Molecular Function and Are Associated with  
490 Sex-Specific Effects on Fertility and Aging. *Curr. Biol.* 25, 2717–2722.  
491 <https://doi.org/10.1016/j.cub.2015.09.012>
- 492 Carlson, J.C., Nidey, N.L., Butali, A., Buxo, C.J., Christensen, K., Deleyiannis, F.W.-D., Hecht,  
493 J.T., Field, L.L., Moreno-Urbe, L.M., Orioli, I.M., Poletta, F.A., Padilla, C., Vieira, A.R.,  
494 Weinberg, S.M., Wehby, G.L., Feingold, E., Murray, J.C., Marazita, M.L., Leslie, E.J.,  
495 2018. Genome-wide interaction studies identify sex-specific risk alleles for  
496 nonsyndromic orofacial clefts. *Genet. Epidemiol.* 42, 664–672.  
497 <https://doi.org/10.1002/gepi.22158>
- 498 Chippindale, A.K., Gibson, J.R., Rice, W.R., 2001. Negative genetic correlation for adult  
499 fitness between sexes reveals ontogenetic conflict in *Drosophila*. *Proc. Natl. Acad.*  
500 *Sci. USA* 98, 1671–1675.
- 501 Cicchetti, D., Rogosch, F.A., Hecht, K.F., Crick, N.R., Hetzel, S., 2014. Moderation of  
502 maltreatment effects on childhood borderline personality symptoms by gender and  
503 oxytocin receptor and FK506 binding protein 5 genes. *Dev. Psychopathol.* 26, 831–  
504 849. <https://doi.org/10.1017/S095457941400042X>
- 505 Clayton, J.A., Collins, F.S., 2014. Policy: NIH to balance sex in cell and animal studies. *Nature*  
506 509, 282–283. <https://doi.org/10.1038/509282a>
- 507 Connallon, T., Clark, A., G., 2014. Evolutionary inevitability of sexual antagonism. *Proc. R.*  
508 *Soc. B Biol. Sci.* 281, 20132123. <https://doi.org/10.1098/rspb.2013.2123>
- 509 Connallon, T., Clark, A.G., 2013. Antagonistic Versus Nonantagonistic Models of Balancing  
510 Selection: Characterizing the Relative Timescales and Hitchhiking Effects of Partial  
511 Selective Sweeps. *Evolution* 67, 908–917. <https://doi.org/10.1111/j.1558-5646.2012.01800.x>
- 512
- 513 Dauvilliers, Y., Neidhart, E., Lecendreux, M., Billiard, M., Tafti, M., 2001. MAO-A and COMT  
514 polymorphisms and gene effects in narcolepsy. *Mol. Psychiatry* 6, 367–372.  
515 <https://doi.org/10.1038/sj.mp.4000911>
- 516 Dixon, A., 2009. Dixon, A. F. (2009) *Sexual selection and the Origins of Human Mating*  
517 *Systems*. Oxford University Press, UK.

- 518 Ellegren, H., Parsch, J., 2007. The evolution of sex-biased genes and sex-biased gene  
519 expression. *Nat Rev Genet* 8, 689–698. <https://doi.org/10.1038/nrg2167>
- 520 Fillingim, R.B., Kaplan, L., Staud, R., Ness, T.J., Glover, T.L., Campbell, C.M., Mogil, J.S.,  
521 Wallace, M.R., 2005. The A118G single nucleotide polymorphism of the mu-opioid  
522 receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. *J. Pain*  
523 *Off. J. Am. Pain Soc.* 6, 159–167. <https://doi.org/10.1016/j.jpain.2004.11.008>
- 524 Fitzpatrick, M.J., 2004. Pleiotropy and the genomic location of sexually selected genes. *Am.*  
525 *Nat.* 163, 800–808. <https://doi.org/10.1086/386297>
- 526 Foerster, K., Coulson, T., Sheldon, B.C., Pemberton, J.M., Clutton-Brock, T., Kruuk, L.E.B.,  
527 2007. Sexually antagonistic genetic variation for fitness in red deer. *Nature* 447,  
528 1107–1110.
- 529 Franck, N., Lanne, T., Astrand, O., Engvall, J., Lindstrom, T., Ostgren, C.J., Nystrom, F.H.,  
530 2012. Cardiovascular risk factors related to the PPARgamma Pro12Ala polymorphism  
531 in patients with type 2 diabetes are gender dependent. *Blood Press.* 21, 122–127.  
532 <https://doi.org/10.3109/08037051.2011.623349>
- 533 Fry, J.D., 2010. The Genomic Location of Sexually Antagonistic Variation: Some Cautionary  
534 Comments. *Evolution* 64, 1510–1516. [https://doi.org/10.1111/j.1558-](https://doi.org/10.1111/j.1558-5646.2009.00898.x)  
535 [5646.2009.00898.x](https://doi.org/10.1111/j.1558-5646.2009.00898.x)
- 536 Garver-Apgar, C.E., Eaton, M.A., Tybur, J.M., Emery Thompson, M., 2011. Evidence of  
537 intralocus sexual conflict: physically and hormonally masculine individuals have more  
538 attractive brothers relative to sisters. *Evol. Hum. Behav.* 32, 423–432.  
539 <https://doi.org/10.1016/j.evolhumbehav.2011.03.005>
- 540 Gastaldi, M., Diziere, S., Defoort, C., Portugal, H., Lairon, D., Darmon, M., Planells, R., 2007.  
541 Sex-specific association of fatty acid binding protein 2 and microsomal triacylglycerol  
542 transfer protein variants with response to dietary lipid changes in the 3-mo Medi-  
543 RIVAGE primary intervention study. *Am. J. Clin. Nutr.* 86, 1633–1641.  
544 <https://doi.org/10.1093/ajcn/86.5.1633>
- 545 Gilks, W.P., Abbott, J.K., Morrow, E.H., 2014. Sex differences in disease genetics: evidence,  
546 evolution, and detection. *Trends Genet.* 30, 453–463.  
547 <https://doi.org/10.1016/j.tig.2014.08.006>
- 548 Gloria-Bottini, F., Bottini, N., Renzetti, G., Bottini, E., 2007. ACP1 and Th class of  
549 immunological disease: evidence of interaction with gender. *Int. Arch. Allergy*  
550 *Immunol.* 143, 170–176. <https://doi.org/10.1159/000099308>
- 551 Grieshop, K., Arnavist, G., 2018. Sex-specific dominance reversal of genetic variation for  
552 fitness. *PLOS Biol.* 16, e2006810. <https://doi.org/10.1371/journal.pbio.2006810>
- 553 Gurevitch, J., Koricheva, J., Mengersen, K., 2013. Handbook of Meta-Analysis In Ecology and  
554 Evolution, Handbook of Meta-analysis in Ecology and Evolution.  
555 <https://doi.org/10.1515/9781400846184>
- 556 Herman, A.I., Conner, T.S., Anton, R.F., Gelernter, J., Kranzler, H.R., Covault, J., 2011.  
557 Variation in the gene encoding the serotonin transporter is associated with a  
558 measure of sociopathy in alcoholics. *Addict. Biol.* 16, 124–132.  
559 <https://doi.org/10.1111/j.1369-1600.2009.00197.x>
- 560 Khramtsova, E.A., Davis, L.K., Stranger, B.E., 2019. The role of sex in the genomics of human  
561 complex traits. *Nat. Rev. Genet.* 20, 173–190. [https://doi.org/10.1038/s41576-018-](https://doi.org/10.1038/s41576-018-0083-1)  
562 [0083-1](https://doi.org/10.1038/s41576-018-0083-1)

- 563 Kim, B., Kim, H., Joo, Y.H., Lim, J., Kim, C.-Y., Song, K., 2010. Sex-different association of DAO  
564 with schizophrenia in Koreans. *Psychiatry Res.* 179, 121–125.  
565 <https://doi.org/10.1016/j.psychres.2008.08.009>
- 566 Kiy, A., Wilhelm, O., Hildebrandt, A., Reuter, M., Sommer, W., 2013. On the genetic basis of  
567 face cognition and its relation to fluid cognitive abilities. *Genes Brain Behav.* 12, 438–  
568 445. <https://doi.org/10.1111/gbb.12034>
- 569 Korner, A., Ma, L., Franks, P.W., Kiess, W., Baier, L.J., Stumvoll, M., Kovacs, P., 2007. Sex-  
570 specific effect of the Val1483Ile polymorphism in the fatty acid synthase gene (FAS)  
571 on body mass index and lipid profile in Caucasian children. *Int. J. Obes.* 2005 31,  
572 353–358. <https://doi.org/10.1038/sj.ijo.0803428>
- 573 Lajeunesse, M., 2013. Recovering missing or partial data from studies: A survey of  
574 conversions and imputations for meta-analysis. pp. 195–206.
- 575 Lande, R., 1980. Sexual dimorphism, sexual selection, and adaptation in polygenic  
576 characters. *Evolution* 34, 292–305.
- 577 Lang, U.E., Hellweg, R., Bajbouj, M., Gaus, V., Sander, T., Gallinat, J., 2008. Gender-  
578 dependent association of a functional NGF polymorphism with anxiety-related  
579 personality traits. *Pharmacopsychiatry* 41, 196–199. <https://doi.org/10.1055/s-0028-1082070>
- 581 Lauritzen, L., Sorensen, L.B., Harslof, L.B., Ritz, C., Stark, K.D., Astrup, A., Dyssegaard, C.B.,  
582 Egelund, N., Michaelsen, K.F., Damsgaard, C.T., 2017. Mendelian randomization  
583 shows sex-specific associations between long-chain. *Am. J. Clin. Nutr.* 106, 88–95.  
584 <https://doi.org/10.3945/ajcn.117.152595>
- 585 Lee, S.K., 2018. Sex as an important biological variable in biomedical research. *BMB Rep.* 51,  
586 167–173. <https://doi.org/10.5483/BMBRep.2018.51.4.034>
- 587 Liu, Y.-H., Chen, Y.-J., Wu, H.-H., Wang, T.-Y., Tsai, F.-J., 2014. Single nucleotide  
588 polymorphisms at the PRR3, ABCF1, and GNL1 genes in the HLA class I region are  
589 associated with Graves' ophthalmopathy in a gender-dependent manner.  
590 *Ophthalmology* 121, 2033–2039. <https://doi.org/10.1016/j.ophtha.2014.04.027>
- 591 Ljungberg, L.U., Ostgren, C.J., Nystrom, F.H., Lanne, T., 2014. Associations of genetic  
592 polymorphisms in the renin-angiotensin system with central aortic and ambulatory  
593 blood pressure in type 2 diabetic patients. *J. Renin-Angiotensin-Aldosterone Syst.*  
594 *JRAAS* 15, 61–68. <https://doi.org/10.1177/1470320312474052>
- 595 McCarthy, J.J., Somji, A., Weiss, L.A., Steffy, B., Vega, R., Barrett-Connor, E., Talavera, G.,  
596 Glynn, R., 2009. Polymorphisms of the scavenger receptor class B member 1 are  
597 associated with insulin resistance with evidence of gene by sex interaction. *J. Clin.*  
598 *Endocrinol. Metab.* 94, 1789–1796. <https://doi.org/10.1210/jc.2008-2800>
- 599 Mills, S.C., Koskela, E., Mappes, T., 2011. Intralocus sexual conflict for fitness: sexually  
600 antagonistic alleles for testosterone. *Proc. R. Soc. B Biol. Sci.* rspb20112340.  
601 <https://doi.org/10.1098/rspb.2011.2340>
- 602 Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group, T.P., 2009. Preferred Reporting  
603 Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLOS*  
604 *Med.* 6, e1000097. <https://doi.org/10.1371/journal.pmed.1000097>
- 605 Morea, A., Cameran, M., Rebuffi, A.G., Marzenta, D., Marangon, O., Picci, L., Zacchello, F.,  
606 Scarpa, M., 2005. Gender-sensitive association of CFTR gene mutations and 5T allele  
607 emerging from a large survey on infertility. *Mol. Hum. Reprod.* 11, 607–614.  
608 <https://doi.org/10.1093/molehr/gah214>

- 609 Morrow, E.H., 2015. The evolution of sex differences in disease. *Biol. Sex Differ.* 6, 5.  
610 <https://doi.org/10.1186/s13293-015-0023-0>
- 611 Morrow, E.H., Connallon, T., 2013. Implications of sex-specific selection for the genetic basis  
612 of disease. *Evol. Appl.* 6, 1208–1217. <https://doi.org/10.1111/eva.12097>
- 613 Nesse, R.M., Williams, G.C., 1994. *Why we get sick: The new science of Darwinian medicine.*  
614 Vintage, New York.
- 615 Ober, C., Loisel, D.A., Gilad, Y., 2008. Sex-specific genetic architecture of human disease. *Nat*  
616 *Rev Genet* 9, 911–922. <https://doi.org/10.1038/nrg2415>
- 617 Ober, C., Pan, L., Phillips, N., Parry, R., Kurina, L.M., 2006. Sex-specific genetic architecture of  
618 asthma-associated quantitative trait loci in a founder population. *Curr. Allergy*  
619 *Asthma Rep.* 6, 241–246. <https://doi.org/10.1007/s11882-006-0041-4>
- 620 Ovadia, G., Shifman, S., 2011. The genetic variation of RELN expression in schizophrenia and  
621 bipolar disorder. *PloS One* 6, e19955. <https://doi.org/10.1371/journal.pone.0019955>
- 622 Padmanabhan, S., Menni, C., Lee, W.K., Laing, S., Brambilla, P., Sega, R., Perego, R., Grassi,  
623 G., Cesana, G., Delles, C., Mancina, G., Dominiczak, A.F., 2010. The effects of sex and  
624 method of blood pressure measurement on genetic associations with blood pressure  
625 in the PAMELA study. *J. Hypertens.* 28, 465–477.  
626 <https://doi.org/10.1097/HJH.0b013e32833594d7>
- 627 Parker, G.A., 1979. SEXUAL SELECTION AND SEXUAL CONFLICT, in: *Sexual Selection and*  
628 *Reproductive Competition in Insects.* Elsevier, pp. 123–166.  
629 <https://doi.org/10.1016/B978-0-12-108750-0.50010-0>
- 630 Parker, G.A., Baker, R.R., Smith, V.G.F., 1972. The origin and evolution of gamete  
631 dimorphism and the male-female phenomenon. *J. Theor. Biol.* 36, 529–553.
- 632 Payne, E.H., Gebregziabher, M., Hardin, J.W., Ramakrishnan, V., Egede, L.E., 2018. An  
633 empirical approach to determine a threshold for assessing overdispersion in Poisson  
634 and negative binomial models for count data. *Commun. Stat. Simul. Comput.* 47,  
635 1722–1738. <https://doi.org/10.1080/03610918.2017.1323223>
- 636 Peng, Y.-M., Lei, S.-F., Guo, Y., Xiong, D.-H., Yan, H., Wang, L., Guo, Y.-F., Deng, H.-W., 2008.  
637 Sex-specific association of the glucocorticoid receptor gene with extreme BMD. *J.*  
638 *Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res.* 23, 247–252.  
639 <https://doi.org/10.1359/jbmr.071017>
- 640 Pennell, T.M., Haas, F.J.H. de, Morrow, E.H., Doorn, G.S. van, 2016. Contrasting effects of  
641 intralocus sexual conflict on sexually antagonistic coevolution. *Proc. Natl. Acad. Sci.*  
642 113, E978–E986. <https://doi.org/10.1073/pnas.1514328113>
- 643 Pennell, T.M., Morrow, E.H., 2013. Two sexes, one genome: the evolutionary dynamics of  
644 intralocus sexual conflict. *Ecol. Evol.* 3, 1819–1834.  
645 <https://doi.org/10.1002/ece3.540>
- 646 Press, O.A., Zhang, W., Gordon, M.A., Yang, D., Haiman, C.A., Azuma, M., Iqbal, S., Lenz, H.-  
647 J., 2011. Gender-related survival differences associated with polymorphic variants of  
648 estrogen receptor-beta (ERbeta) in patients with metastatic colon cancer.  
649 *Pharmacogenomics J.* 11, 375–382. <https://doi.org/10.1038/tpj.2010.45>
- 650 Price, J.S., Strong, J., Eliassen, J., McQueeney, T., Miller, M., Padula, C.B., Shear, P., Lisdahl, K.,  
651 2013. Serotonin transporter gene moderates associations between mood, memory  
652 and hippocampal volume. *Behav. Brain Res.* 242, 158–165.  
653 <https://doi.org/10.1016/j.bbr.2012.11.013>
- 654 Rice, W.R., 1992. Sexually antagonistic genes: experimental evidence. *Science* 256, 1436–  
655 1439. <https://doi.org/10.1126/science.1604317>



- 656 Rice, W.R., 1984. Sex chromosomes and the evolution of sexual dimorphism. *Evolution* 38,  
657 735–742.
- 658 Rigby, N., Kulathinal, R.J., 2015. Genetic Architecture of Sexual Dimorphism in Humans. *J.*  
659 *Cell. Physiol.* 230, 2304–2310. <https://doi.org/10.1002/jcp.24979>
- 660 Rostant, W.G., Kay, C., Wedell, N., Hosken, D.J., 2015. Sexual conflict maintains variation at  
661 an insecticide resistance locus. *BMC Biol.* 13. [https://doi.org/10.1186/s12915-015-](https://doi.org/10.1186/s12915-015-0143-3)  
662 0143-3
- 663 Ruzicka, F., Connallon, T., 2020. Is the X chromosome a hot spot for sexually antagonistic  
664 polymorphisms? Biases in current empirical tests of classical theory. *Proc. R. Soc. B.*  
665 <https://doi.org/10.1098/rspb.2020.1869>
- 666 Ruzicka, F., Dutoit, L., Czappon, P., Jordan, C.Y., Li, X.-Y., Olito, C., Runemark, A., Svensson,  
667 E.I., Yazdi, H.P., Connallon, T., 2020. The search for sexually antagonistic genes:  
668 Practical insights from studies of local adaptation and statistical genomics. *Evol. Lett.*  
669 4–5, 398–415. <https://doi.org/10.1002/evl3.192>
- 670 Ruzicka, F., Hill, M.S., Pennell, T.M., Flis, I., Ingleby, F.C., Mott, R., Fowler, K., Morrow, E.H.,  
671 Reuter, M., 2019. Genome-wide sexually antagonistic variants reveal long-standing  
672 constraints on sexual dimorphism in fruit flies. *PLoS Biol.* 17, e3000244.
- 673 Sainz, J., Rudolph, A., Hoffmeister, M., Frank, B., Brenner, H., Chang-Claude, J., Hemminki,  
674 K., Forsti, A., 2012. Effect of type 2 diabetes predisposing genetic variants on  
675 colorectal cancer risk. *J. Clin. Endocrinol. Metab.* 97, E845-851.  
676 <https://doi.org/10.1210/jc.2011-2565>
- 677 Sangalli, A., Orlandi, E., Poli, A., Maurichi, A., Santinami, M., Nicolis, M., Ferronato, S.,  
678 Malerba, G., Rodolfo, M., Gomez Lira, M., 2017. Sex-specific effect of RNASEL  
679 rs486907 and miR-146a rs2910164 polymorphisms' interaction as a susceptibility  
680 factor for melanoma skin cancer. *Melanoma Res.* 27, 309–314.  
681 <https://doi.org/10.1097/CMR.0000000000000360>
- 682 Schneider, K.K., Hule, L., Schote, A.B., Meyer, J., Frings, C., 2015. Sex matters! Interactions of  
683 sex and polymorphisms of a cholinergic receptor gene (CHRNA5) modulate response  
684 speed. *Neuroreport* 26, 186–191. <https://doi.org/10.1097/WNR.0000000000000313>
- 685 Schuurhof, A., Bont, L., Siezen, C.L.E., Hodemaekers, H., van Houwelingen, H.C., Kimman,  
686 T.G., Hoebee, B., Kimpen, J.L.L., Janssen, R., 2010. Interleukin-9 polymorphism in  
687 infants with respiratory syncytial virus infection: an opposite effect in boys and girls.  
688 *Pediatr. Pulmonol.* 45, 608–613. <https://doi.org/10.1002/ppul.21229>
- 689 Shalev, I., Lerer, E., Israel, S., Uzefovsky, F., Gritsenko, I., Mankuta, D., Ebstein, R.P., Kaitz,  
690 M., 2009. BDNF Val66Met polymorphism is associated with HPA axis reactivity to  
691 psychological stress characterized by genotype and gender interactions.  
692 *Psychoneuroendocrinology* 34, 382–388.  
693 <https://doi.org/10.1016/j.psyneuen.2008.09.017>
- 694 Short, R.V., 1979. Sexual selection and its component parts, somatic and genital selection, as  
695 illustrated by man and the great apes. *Adv. Study Behav.* 9, 131–158.
- 696 Sjoberg, R.L., Nilsson, K.W., Nordquist, N., Ohrvik, J., Leppert, J., Lindstrom, L., Orelund, L.,  
697 2006. Development of depression: sex and the interaction between environment  
698 and a promoter polymorphism of the serotonin transporter gene. *Int. J.*  
699 *Neuropsychopharmacol.* 9, 443–449. <https://doi.org/10.1017/S1461145705005936>
- 700 Stearns, S.C., Govindaraju, D.R., Ewbank, D., Byars, S.G., 2012. Constraints on the  
701 coevolution of contemporary human males and females. *Proc. R. Soc. B Biol. Sci.* 279,  
702 4836–4844. <https://doi.org/10.1098/rspb.2012.2024>

703 Stulp, G., Kuijper, B., Buunk, A.P., Pollet, T.V., Verhulst, S., 2012. Intralocus sexual conflict  
704 over human height. *Biol. Lett.* <https://doi.org/10.1098/rsbl.2012.0590>  
705 Winkler, T.W., Justice, A.E., Graff, M., Barata, L., Feitosa, M.F., Chu, S., Czajkowski, J., Esko,  
706 T., Fall, T., Kilpeläinen, T.O., Lu, Y., Mägi, R., Mihailov, E., Pers, T.H., Rieger, S.,  
707 Teumer, A., Ehret, G.B., Ferreira, T., Heard-Costa, N.L., Karjalainen, J., Lagou, V.,  
708 Mahajan, A., Neinast, M.D., Prokopenko, I., Simino, J., Teslovich, T.M., Jansen, R.,  
709 Westra, H.-J., White, C.C., Absher, D., Ahluwalia, T.S., Ahmad, S., Albrecht, E., Alves,  
710 A.C., Bragg-Gresham, J.L., Craen, A.J.M. de, Bis, J.C., Bonnefond, A., Boucher, G.,  
711 Cadby, G., Cheng, Y.-C., Chiang, C.W.K., Delgado, G., Demirkan, A., Dueker, N.,  
712 Eklund, N., Eiriksdottir, G., Eriksson, J., Feenstra, B., Fischer, K., Frau, F., Galesloot,  
713 T.E., Geller, F., Goel, A., Gorski, M., Grammer, T.B., Gustafsson, S., Haitjema, S.,  
714 Hottenga, J.-J., Huffman, J.E., Jackson, A.U., Jacobs, K.B., Johansson, Å., Kaakinen, M.,  
715 Kleber, M.E., Lahti, J., Leach, I.M., Lehne, B., Liu, Y., Lo, K.S., Lorentzon, M., Luan, J.,  
716 Madden, P.A.F., Mangino, M., McKnight, B., Medina-Gomez, C., Monda, K.L.,  
717 Montasser, M.E., Müller, G., Müller-Nurasyid, M., Nolte, I.M., Panoutsopoulou, K.,  
718 Pascoe, L., Paternoster, L., Rayner, N.W., Renström, F., Rizzi, F., Rose, L.M., Ryan,  
719 K.A., Salo, P., Sanna, S., Scharnagl, H., Shi, J., Smith, A.V., Southam, L., Stančáková, A.,  
720 Steinthorsdottir, V., Strawbridge, R.J., Sung, Y.J., Tachmazidou, I., Tanaka, T.,  
721 Thorleifsson, G., Trompet, S., Pervjakova, N., Tyrer, J.P., Vandenput, L., Laan, S.W.  
722 van der, Velde, N. van der, Setten, J. van, Vliet-Ostaptchouk, J.V. van, Verweij, N.,  
723 Vlachopoulou, E., Waite, L.L., Wang, S.R., Wang, Z., Wild, S.H., Willenborg, C., Wilson,  
724 J.F., Wong, A., Yang, J., Yengo, L., Yerges-Armstrong, L.M., Yu, L., Zhang, W., Zhao,  
725 J.H., Andersson, E.A., Bakker, S.J.L., Baldassarre, D., Banasik, K., Barcella, M.,  
726 Barlassina, C., Bellis, C., Benaglio, P., Blangero, J., Blüher, M., Bonnet, F.,  
727 Bonnycastle, L.L., Boyd, H.A., Bruinenberg, M., Buchman, A.S., Campbell, H., Chen,  
728 Y.-D.I., Chines, P.S., Claudi-Boehm, S., Cole, J., Collins, F.S., Geus, E.J.C. de, Groot,  
729 L.C.P.G.M. de, Dimitriou, M., Duan, J., Enroth, S., Eury, E., Farmaki, A.-E., Forouhi,  
730 N.G., Friedrich, N., Gejman, P.V., Gigante, B., Glorioso, N., Go, A.S., Gottesman, O.,  
731 Gräßler, J., Grallert, H., Grarup, N., Gu, Y.-M., Broer, L., Ham, A.C., Hansen, T., Harris,  
732 T.B., Hartman, C.A., Hassinen, M., Hastie, N., Hattersley, A.T., Heath, A.C., Henders,  
733 A.K., Hernandez, D., Hillege, H., Holmen, O., Hovingh, K.G., Hui, J., Husemoen, L.L.,  
734 Hutri-Kähönen, N., Hysi, P.G., Illig, T., Jager, P.L.D., Jalilzadeh, S., Jørgensen, T.,  
735 Jukema, J.W., Juonala, M., Kanoni, S., Karaleftheri, M., Khaw, K.T., Kinnunen, L.,  
736 Kittner, S.J., Koenig, W., Kolcic, I., Kovacs, P., Krarup, N.T., Kratzer, W., Krüger, J.,  
737 Kuh, D., Kumari, M., Kyriakou, T., Langenberg, C., Lannfelt, L., Lanzani, C., Lotay, V.,  
738 Launer, L.J., Leander, K., Lindström, J., Linneberg, A., Liu, Y.-P., Lobbens, S., Luben, R.,  
739 Lyssenko, V., Männistö, S., Magnusson, P.K., McArdle, W.L., Menni, C., Merger, S.,  
740 Milani, L., Montgomery, G.W., Morris, A.P., Narisu, N., Nelis, M., Ong, K.K., Palotie,  
741 A., Pérusse, L., Pichler, I., Pilia, M.G., Pouta, A., Rheinberger, M., Ribel-Madsen, R.,  
742 Richards, M., Rice, K.M., Rice, T.K., Rivolta, C., Salomaa, V., Sanders, A.R., Sarzynski,  
743 M.A., Scholtens, S., Scott, R.A., Scott, W.R., Sebert, S., Sengupta, S., Sennblad, B.,  
744 Seufferlein, T., Silveira, A., Slagboom, P.E., Smit, J.H., Sparsø, T.H., Stirrups, K., Stolk,  
745 R.P., Stringham, H.M., Swertz, M.A., Swift, A.J., Syvänen, A.-C., Tan, S.-T., Thorand,  
746 B., Tönjes, A., Tremblay, A., Tsfantakis, E., Most, P.J. van der, Völker, U., Vohl, M.-C.,  
747 Vonk, J.M., Waldenberger, M., Walker, R.W., Wennauer, R., Widén, E., Willemsen,  
748 G., Wilsgaard, T., Wright, A.F., Zillikens, M.C., Dijk, S.C. van, Schoor, N.M. van,  
749 Asselbergs, F.W., Bakker, P.I.W. de, Beckmann, J.S., Beilby, J., Bennett, D.A.,

750 Bergman, R.N., Bergmann, S., Böger, C.A., Boehm, B.O., Boerwinkle, E., Boomsma,  
751 D.I., Bornstein, S.R., Bottinger, E.P., Bouchard, C., Chambers, J.C., Chanock, S.J.,  
752 Chasman, D.I., Cucca, F., Cusi, D., Dedoussis, G., Erdmann, J., Eriksson, J.G., Evans,  
753 D.A., Faire, U. de, Farrall, M., Ferrucci, L., Ford, I., Franke, L., Franks, P.W., Froguel, P.,  
754 Gansevoort, R.T., Gieger, C., Grönberg, H., Gudnason, V., Gyllensten, U., Hall, P.,  
755 Hamsten, A., Harst, P. van der, Hayward, C., Heliövaara, M., Hengstenberg, C., Hicks,  
756 A.A., Hingorani, A., Hofman, A., Hu, F., Huikuri, H.V., Hveem, K., James, A.L., Jordan,  
757 J.M., Jula, A., Kähönen, M., Kajantie, E., Kathiresan, S., Kiemenev, L.A.L.M., Kivimäki,  
758 M., Knekt, P.B., Koistinen, H.A., Kooner, J.S., Koskinen, S., Kuusisto, J., Maerz, W.,  
759 Martin, N.G., Laakso, M., Lakka, T.A., Lehtimäki, T., Lettre, G., Levinson, D.F., Lind, L.,  
760 Lokki, M.-L., Mäntyselkä, P., Melbye, M., Metspalu, A., Mitchell, B.D., Moll, F.L.,  
761 Murray, J.C., Musk, A.W., Nieminen, M.S., Njølstad, I., Ohlsson, C., Oldehinkel, A.J.,  
762 Oostra, B.A., Palmer, L.J., Pankow, J.S., Pasterkamp, G., Pedersen, N.L., Pedersen, O.,  
763 Penninx, B.W., Perola, M., Peters, A., Polašek, O., Pramstaller, P.P., Psaty, B.M., Qi,  
764 L., Quertermous, T., Raitakari, O.T., Rankinen, T., Rauramaa, R., Ridker, P.M., Rioux,  
765 J.D., Rivadeneira, F., Rotter, J.I., Rudan, I., Ruijter, H.M. den, Saltevo, J., Sattar, N.,  
766 Schunkert, H., Schwarz, P.E.H., Shuldiner, A.R., Sinisalo, J., Snieder, H., Sørensen,  
767 T.I.A., Spector, T.D., Staessen, J.A., Stefania, B., Thorsteinsdottir, U., Stumvoll, M.,  
768 Tardif, J.-C., Tremoli, E., Tuomilehto, J., Uitterlinden, A.G., Uusitupa, M., Verbeek,  
769 A.L.M., Vermeulen, S.H., Viikari, J.S., Vitart, V., Völzke, H., Vollenweider, P., Waeber,  
770 G., Walker, M., Wallaschofski, H., Wareham, N.J., Watkins, H., Zeggini, E.,  
771 Consortium, C., Consortium, D., Consortium, G., Consortium, G.-Bpg., Consortium, I.,  
772 Consortium, M., Chakravarti, A., Clegg, D.J., Cupples, L.A., Gordon-Larsen, P., Jaquish,  
773 C.E., Rao, D.C., Abecasis, G.R., Assimes, T.L., Barroso, I., Berndt, S.I., Boehnke, M.,  
774 Deloukas, P., Fox, C.S., Groop, L.C., Hunter, D.J., Ingelsson, E., Kaplan, R.C., McCarthy,  
775 M.I., Mohlke, K.L., O'Connell, J.R., Schlessinger, D., Strachan, D.P., Stefansson, K.,  
776 Duijn, C.M. van, Hirschhorn, J.N., Lindgren, C.M., Heid, I.M., North, K.E., Borecki, I.B.,  
777 Kutalik, Z., Loos, R.J.F., 2015. The Influence of Age and Sex on Genetic Associations  
778 with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study.  
779 PLOS Genet. 11, e1005378. <https://doi.org/10.1371/journal.pgen.1005378>  
780 Wise, A.L., Gyi, L., Manolio, T.A., 2013. eXclusion: Toward Integrating the X Chromosome in  
781 Genome-wide Association Analyses. *Am. J. Hum. Genet.* 92, 643–647.  
782 <https://doi.org/10.1016/j.ajhg.2013.03.017>  
783 Wong, S.Y.S., Lau, E.M.C., Li, M., Chung, T., Sham, A., Woo, J., 2005. The prevalence of Apo  
784 E4 genotype and its relationship to bone mineral density in Hong Kong Chinese. *J.*  
785 *Bone Miner. Metab.* 23, 261–265. <https://doi.org/10.1007/s00774-004-0593-0>  
786 Wu, K., Chen, C., Moyzis, R.K., Greenberger, E., Yu, Z., 2016. Gender Interacts with Opioid  
787 Receptor Polymorphism A118G and Serotonin Receptor Polymorphism -1438 A/G on  
788 Speed-Dating Success. *Hum. Nat. Hawthorne N* 27, 244–260.  
789 <https://doi.org/10.1007/s12110-016-9257-8>  
790 Youssef, S.S., Abd El Aal, A.M., Nasr, A.S., el Zanaty, T., Seif, S.M., 2013. Interleukin-12B gene  
791 polymorphism frequencies in Egyptians and sex-related susceptibility to hepatitis C  
792 infection. *J. Interferon Cytokine Res. Off. J. Int. Soc. Interferon Cytokine Res.* 33, 415–  
793 419. <https://doi.org/10.1089/jir.2012.0161>

## 794 Supplementary Material

795

796 Both stages of the PubMed literature search employed a Species filter set to Humans only.

797

798 Stage 1 Search term:

799 (((((((((((((((((((sexual antagonism[Title/Abstract] AND locus[Title/Abstract]) OR (sexual  
800 antagonism[Title/Abstract] AND loci[Title/Abstract])) OR (sexual antagonism[Title/Abstract]  
801 AND gene[Title/Abstract])) OR (sexual antagonism[Title/Abstract] AND snp[Title/Abstract]))  
802 OR (sexual antagonism[Title/Abstract] AND polymorphism[Title/Abstract])) OR (sexual  
803 antagonism[Title/Abstract] AND variant[Title/Abstract])) OR (sexual  
804 antagonism[Title/Abstract] AND allele[Title/Abstract])) OR (sexually  
805 antagonistic[Title/Abstract] AND locus[Title/Abstract])) OR (sexually  
806 antagonistic[Title/Abstract] AND loci[Title/Abstract])) OR (sexually  
807 antagonistic[Title/Abstract] AND gene[Title/Abstract])) OR (sexually  
808 antagonistic[Title/Abstract] AND snp[Title/Abstract])) OR (sexually  
809 antagonistic[Title/Abstract] AND polymorphism[Title/Abstract])) OR (sexually  
810 antagonistic[Title/Abstract] AND variant[Title/Abstract])) OR (sexually  
811 antagonistic[Title/Abstract] AND allele[Title/Abstract])) OR (intralocus sexual  
812 conflict[Title/Abstract] AND locus[Title/Abstract])) OR (intralocus sexual  
813 conflict[Title/Abstract] AND loci[Title/Abstract])) OR (intralocus sexual  
814 conflict[Title/Abstract] AND gene[Title/Abstract])) OR (intralocus sexual  
815 conflict[Title/Abstract] AND snp[Title/Abstract])) OR (intralocus sexual  
816 conflict[Title/Abstract] AND polymorphism[Title/Abstract])) OR (intralocus sexual  
817 conflict[Title/Abstract] AND variant[Title/Abstract])) OR (intralocus sexual  
818 conflict[Title/Abstract] AND allele[Title/Abstract])

819

820


821

822 Stage 2 Search term:

823 (((gender[Title/Abstract] AND  
824 opposite[Title/Abstract] AND locus[Title/Abstract]) OR (gender[Title/Abstract] AND  
825 opposite[Title/Abstract] AND loci[Title/Abstract])) OR (gender[Title/Abstract] AND  
826 opposite[Title/Abstract] AND gene[Title/Abstract])) OR (gender[Title/Abstract] AND  
827 opposite[Title/Abstract] AND snp[Title/Abstract])) OR (gender[Title/Abstract] AND  
828 opposite[Title/Abstract] AND polymorphism[Title/Abstract])) OR (gender[Title/Abstract]  
829 AND opposite[Title/Abstract] AND variant[Title/Abstract])) OR (sex[Title/Abstract] AND  
830 opposite[Title/Abstract] AND locus[Title/Abstract])) OR (sex[Title/Abstract] AND  
831 opposite[Title/Abstract] AND loci[Title/Abstract])) OR (sex[Title/Abstract] AND  
832 opposite[Title/Abstract] AND gene[Title/Abstract])) OR (sex[Title/Abstract] AND  
833 opposite[Title/Abstract] AND snp[Title/Abstract])) OR (sex[Title/Abstract] AND  
834 opposite[Title/Abstract] AND polymorphism[Title/Abstract])) OR (sex[Title/Abstract] AND  
835 opposite[Title/Abstract] AND variant[Title/Abstract])) OR (sex dependent[Title/Abstract]  
836 AND locus[Title/Abstract])) OR (sex dependent[Title/Abstract] AND loci[Title/Abstract])) OR  
837 (sex dependent[Title/Abstract] AND gene[Title/Abstract])) OR (sex  
838 dependent[Title/Abstract] AND snp[Title/Abstract])) OR (sex dependent[Title/Abstract] AND  
839 polymorphism[Title/Abstract])) OR (sex dependent[Title/Abstract] AND  
840 variant[Title/Abstract])) OR (sex different[Title/Abstract] AND locus[Title/Abstract])) OR (sex

841 different[Title/Abstract] AND loci[Title/Abstract])) OR (sex different[Title/Abstract] AND  
842 gene[Title/Abstract])) OR (sex different[Title/Abstract] AND snp[Title/Abstract])) OR (sex  
843 different[Title/Abstract] AND polymorphism[Title/Abstract])) OR (sex  
844 different[Title/Abstract] AND variant[Title/Abstract])) OR (gender-dependent[Title/Abstract]  
845 AND locus[Title/Abstract])) OR (gender-dependent[Title/Abstract] AND loci[Title/Abstract]))  
846 OR (gender-dependent[Title/Abstract] AND gene[Title/Abstract])) OR (gender-  
847 dependent[Title/Abstract] AND snp[Title/Abstract])) OR (gender-dependent[Title/Abstract]  
848 AND polymorphism[Title/Abstract])) OR (gender-dependent[Title/Abstract] AND  
849 variant[Title/Abstract])) OR (male[Title/Abstract] AND female[Title/Abstract] AND  
850 opposite[Title/Abstract] AND locus[Title/Abstract])) OR (male[Title/Abstract] AND  
851 female[Title/Abstract] AND opposite[Title/Abstract] AND loci[Title/Abstract])) OR  
852 (male[Title/Abstract] AND female[Title/Abstract] AND opposite[Title/Abstract] AND  
853 gene[Title/Abstract])) OR (male[Title/Abstract] AND female[Title/Abstract] AND  
854 opposite[Title/Abstract] AND snp[Title/Abstract])) OR (male[Title/Abstract] AND  
855 female[Title/Abstract] AND opposite[Title/Abstract] AND polymorphism[Title/Abstract])) OR  
856 (male[Title/Abstract] AND female[Title/Abstract] AND opposite[Title/Abstract] AND  
857 variant[Title/Abstract])) OR (men[Title/Abstract] AND women[Title/Abstract] AND  
858 opposite[Title/Abstract] AND locus[Title/Abstract])) OR (men[Title/Abstract] AND  
859 women[Title/Abstract] AND opposite[Title/Abstract] AND loci[Title/Abstract])) OR  
860 (men[Title/Abstract] AND women[Title/Abstract] AND opposite[Title/Abstract] AND  
861 gene[Title/Abstract])) OR (men[Title/Abstract] AND women[Title/Abstract] AND  
862 opposite[Title/Abstract] AND snp[Title/Abstract])) OR (men[Title/Abstract] AND  
863 women[Title/Abstract] AND opposite[Title/Abstract] AND polymorphism[Title/Abstract]))  
864 OR (men[Title/Abstract] AND women[Title/Abstract] AND opposite[Title/Abstract] AND  
865 variant[Title/Abstract])) OR (boys[Title/Abstract] AND girls[Title/Abstract] AND  
866 opposite[Title/Abstract] AND locus[Title/Abstract])) OR (boys[Title/Abstract] AND  
867 girls[Title/Abstract] AND opposite[Title/Abstract] AND loci[Title/Abstract])) OR  
868 (boys[Title/Abstract] AND girls[Title/Abstract] AND opposite[Title/Abstract] AND  
869 gene[Title/Abstract])) OR (boys[Title/Abstract] AND girls[Title/Abstract] AND  
870 opposite[Title/Abstract] AND snp[Title/Abstract])) OR (boys[Title/Abstract] AND  
871 girls[Title/Abstract] AND opposite[Title/Abstract] AND polymorphism[Title/Abstract])) OR  
872 (boys[Title/Abstract] AND girls[Title/Abstract] AND opposite[Title/Abstract] AND  
873 variant[Title/Abstract])) OR (gender[Title/Abstract] AND opposite[Title/Abstract] AND  
874 allele[Title/Abstract])) OR (sex[Title/Abstract] AND opposite[Title/Abstract] AND  
875 allele[Title/Abstract])) OR (sex dependent[Title/Abstract] AND allele[Title/Abstract])) OR  
876 (sex different[Title/Abstract] AND allele[Title/Abstract])) OR (gender-  
877 dependent[Title/Abstract] AND allele[Title/Abstract])) OR (male[Title/Abstract] AND  
878 female[Title/Abstract] AND opposite[Title/Abstract] AND allele[Title/Abstract])) OR  
879 (men[Title/Abstract] AND women[Title/Abstract] AND opposite[Title/Abstract] AND  
880 allele[Title/Abstract])) OR (boys[Title/Abstract] AND girls[Title/Abstract] AND  
881 opposite[Title/Abstract] AND allele[Title/Abstract])  
882  
883  
884  
885  
886


887



888  
889

890 **Figure S1. Study reported effect allele frequencies and database allele frequencies are**  
891 **strongly correlated.** The correlation between reported effect allele frequency and  
892 frequencies for the same alleles obtained from the 1000 genomes database (0.94). Filled  
893 circles represent disease risk/severity related variants while open circles represent complex  
894 trait variants.


895



896  
897

898 **Figure S2. Relationship between study sample size and average extracted effect size**  
899 **across all studies.**

900




901  
902  
903  
904  
905  
906

**Figure S3. Female effect size and male effect size are negatively correlated in SA alleles.**  
Effect size (Cohen's D) of variants in females against effect size in males. Triangular points represent sex-opposite complex trait variants, circular points represent disease risk/severity variants.



907



908  
909

910 **Figure S4. The relationship between effect allele frequency and effect size ratio, grouped**  
911 **by trait class.** Points to the right of the vertical dotted line have a greater negative effect than  
912 positive. **A.** Disease risk/severity variants. **B.** Complex traits. Point size is based on the variance  
913 of the effect size ratio, with smaller variance having larger point sizes and greater weighting  
914 in the statistical model.